Qi Q, Zhou Z, Ma J, Yao B, Chen L
Department of Reproductive Medicine, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjng 210002, China.
Department of Reproductive Medicine, Jinling Hospital, Affiliated Hospital of Medical School of Nanjing University, Nanjing, 210002, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2024 Nov 20;44(11):2184-2191. doi: 10.12122/j.issn.1673-4254.2024.11.15.
We report a case of application of third-generation sequencing (TGS) combined with preimplantation genetic testing (PGT) for successful prevention of hereditary spastic paraplegia (HSP) caused by SPAST gene mutations and assess the value of PGT-M and TGS in managing hereditary spastic paraplegia.
A family affected by HSP underwent whole exon sequencing (WES), and a c.1699G>T mutation in the SPAST gene was identified. The mutation site in the proband was confirmed through Sanger sequencing. A single nucleotide polymorphism (SNP) site flanking the SPAST gene mutation was selected as the genetic linkage marker, and a SNP haplotype carrying the mutated gene was constructed. Ovarian stimulation using an antagonist regimen was performed for oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) and embryo culture. Blastocyst trophectoderm cells were biopsied for preimplantation genetic testing for monogenic disorders (PGT-M) to allow the selection of disease-free embryos for transfer.
In this cycle, a total of 20 oocytes were retrieved, among which 18 were successfully fertilized to result in 12 blastocysts eligible for biopsy. Genetic testing revealed that all the 12 blastocysts were successfully amplified and confirmed as euploidy. Among them, 8 blastocysts did not carry paternal mutations, and a high-quality euploid embryo was selected for frozen embryo transfer (FET). Subsequent amniotic fluid testing during pregnancy confirmed the absence of paternal mutations in the fetus, resulting in the birth of a healthy baby girl.
For cases of genetic diseases with missing pedigree data, the application of third-generation sequencing and PGT-M technique can effectively block vertical transmission of SPAST gene mutation to the offspring, avoid pregnancy with an aneuploid embryo, and help families with autosomal dominant HSP obtain healthy offsprings.
我们报告一例应用第三代测序(TGS)联合植入前基因检测(PGT)成功预防由SPAST基因突变引起的遗传性痉挛性截瘫(HSP)的病例,并评估PGT-M和TGS在管理遗传性痉挛性截瘫中的价值。
一个受HSP影响的家庭接受了全外显子测序(WES),并在SPAST基因中鉴定出一个c.1699G>T突变。通过桑格测序法对先证者的突变位点进行了确认。选择SPAST基因突变侧翼的单核苷酸多态性(SNP)位点作为遗传连锁标记,并构建携带突变基因的SNP单倍型。采用拮抗剂方案进行卵巢刺激以获取卵母细胞,随后进行卵胞浆内单精子注射(ICSI)和胚胎培养。对囊胚滋养外胚层细胞进行单基因疾病植入前基因检测(PGT-M),以便选择无病胚胎进行移植。
在这个周期中,共获取了20个卵母细胞,其中18个成功受精,产生了12个符合活检条件的囊胚。基因检测显示,所有12个囊胚均成功扩增并被确认为整倍体。其中,8个囊胚未携带父系突变,选择了一个高质量的整倍体胚胎进行冻胚移植(FET)。孕期后续的羊水检测证实胎儿不存在父系突变,一名健康女婴出生。
对于家系数据缺失的遗传病病例,应用第三代测序和PGT-M技术可有效阻断SPAST基因突变向后代的垂直传递,避免非整倍体胚胎妊娠,并帮助常染色体显性遗传性痉挛性截瘫家庭获得健康后代。